Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

被引:5
|
作者
Pirola, Carlos Jose [1 ,2 ,6 ,8 ]
Salatino, Adrian [3 ]
Gianotti, Tomas Fernandez [1 ]
Castano, Gustavo Osvaldo [4 ]
Garaycoechea, Martin [5 ]
Sookoian, Silvia [2 ,6 ,7 ,8 ]
机构
[1] Maimonides Univ, Translat Hlth Res Ctr CENITRES, Syst Biol Complex Dis, Buenos Aires, Argentina
[2] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, Argentina
[3] Max Planck Inst Immunobiol & Epigenet, Bioinformat Facil, D-79108 Freiburg, Germany
[4] Hosp Abel Zubizarreta, Med & Surg Dept, Liver Unit, Buenos Aires, Argentina
[5] Hosp Alta Complej Red El Cruce, Dept Surg, Florencio Varela, Argentina
[6] Maimonides Univ, Fac Hlth Sci, Buenos Aires, DF, Argentina
[7] Maimonides Univ, Translat Hlth Res Ctr CENITRES, Clin & Mol Hepatol, Buenos Aires, Argentina
[8] Hidalgo 775,C1405BCK, Buenos Aires, Argentina
来源
EBIOMEDICINE | 2024年 / 101卷
关键词
NAFLD; MASLD; Microbiota; Epigenetics; HDAC; HAT; 5-Hydroxymethylcytosine; CHAIN FATTY-ACIDS; BUTYRATE; GENE;
D O I
10.1016/j.ebiom.2024.104996
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The pathogenesis of MASLD (metabolic dysfunction -associated steatotic liver disease), including its severe clinical forms, involves complex processes at all levels of biological organization. This study examined the potential link between the liver microbiome profile and epigenetic factors. Methods Liver microbial DNA composition was analysed using high throughput 16S rRNA gene sequencing in 116 individuals, with 55% being female, across the spectrum of liver disease severity. Total activity of histone deacetylases (HDACs) and acetyltransferases (HATs) was assayed in nuclear extracts from fresh liver samples. In addition, we measured the global 5-hydroxymethylcytosine (5-hmC) levels of liver DNA. Findings Patients with MASLD showed a 2.07 -fold increase (p = 0.013) in liver total HAT activity. Moreover, a correlation was observed between liver total HAT activity and the score for histological steatosis (Spearman's R = 0.60, p = 1.0E-3) and disease severity (R = 0.40, p = 2.0E-2). Liver HAT and HDAC activities also showed associations with the abundance of several liver bacterial DNAs. Additionally, liver global levels of 5-hmC showed negative correlation with the read number of Bacteroidetes (R = -0.62, p = 9.3E-4) and Gammaproteobacteria (R = -0.43, p = 3.2E-2), while it was positively correlated with the abundance of Acidobacteria (R = 0.42, p = 4.1E-2) and Actinobacteria (R = 0.47, p = 1.8E-2). Interpretation The host liver epigenome, including the activity of enzymes involved in maintaining the balance between protein acetylation and deacetylation and the global DNA hydroxy-methylation status, may be the target of microbial signals.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Platelet dynamics in metabolic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and liver cirrhosis
    Zoncape, Mirko
    Castelli, Marco
    Sacerdoti, David
    Minuz, Pietro
    Dalbeni, Andrea
    JOURNAL OF HEPATOLOGY, 2024, 80 : S492 - S493
  • [22] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [23] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86
  • [24] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [25] Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
    Chen, Jiaxin
    Jian, Linge
    Guo, Yangkun
    Tang, Chengwei
    Huang, Zhiyin
    Gao, Jinhang
    ANTIOXIDANTS, 2024, 13 (06)
  • [26] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [27] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [28] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [29] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [30] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)